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Purpose: To compare the short-term effects of intravitreal triamcinolone acetonide (IVTA) with those of intravitreal 
bevacizumab (IVB) injection for diabetic macular edema (DME).
Methods: The present retrospective, comparative case study included 58 eyes of 35 consecutive patients (IVTA 
group, 20 eyes; IVB group, 38 eyes) with DME. IVTA (4 mg) or IVB (1.25 mg) injection was performed under local 
anesthesia. The effects of injection for DME were evaluated using best-corrected visual acuity (BCVA), central 
macular thickness (CMT) by optical coherence tomography and intraocular pressure (IOP) by applanation 
tonometer. Patients underwent eye examinations, including BCVA, CMT, and IOP at pre-injection, 2, 4, and 8 
weeks after injection.
Results: BCVA (logarithm of the minimum angle of resolution) ± SD at pre-injection, 2, 4, and 8 weeks after injection 
was 0.67 ± 0.40, 0.56 ± 0.35 (p = 0.033), 0.55 ± 0.33 (p = 0.041), and 0.43 ± 0.31 (p = 0.001) in the IVTA group 
and 0.51 ± 0.31, 0.42 ± 0.26 (p = 0.003), 0.43 ± 0.32 (p = 0.001), and 0.43 ± 0.27 (p = 0.015) in the IVB group, 
respectively. CMT (μm) ± SD at pre-injection, 2, 4, and 8 weeks after injection was 400.4 ± 94.9, 332.8 ± 47.4 (p 
= 0.002), 287.5 ± 49.1 (p = 0.007), and 282.5 ± 49.6 (p = 0.043) in the IVTA group and 372.6 ± 99.5, 323.2 ± 72.4 
(p = 0.077), 360.9 ± 50.3 (p = 0.668), 368.2 ± 88.6 (p = 0.830) in the IVB group, respectively.
Conclusions: The effects of IVTA for BCVA were more favorable than were those of IVB and were consistent 
throughout the eight weeks after injection. IVTA significantly reduced CMT during the eight weeks after injection, 
while IVB did not.
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Macular edema is the most important manifestation of 
non-proliferative diabetic retinopathy and is a predominant 
cause of legal blindness in diabetic patients [1]. Among treatments 
under investigation for diabetic macular edema (DME), in-
travitreal injection of triamcinolone acetonide [2-9] and anti- 
angiogenic agents, such as bevacizumab [10,11], pegaptanib 
[12] and ranibizumab [13], have been reported to have favor-
able short-term anatomical and visual results in patients with 
DME. Recently, several promising results have been shown 
in different studies regarding the treatment of refractory dia-
betic macular edema with intravitreal triamcinolone aceto-
nide (IVTA) and intravitreal bevacizumab (IVB) [4,14,15]. 
Due to the promising preliminary study results, the anatomi-
cal and visual acuity outcomes associated with IVTA in the 
management of DME were compared with those of IVB in 
the present study. 
Materials and Methods
The present retrospective, comparative case study in-
cluded 58 eyes of 35 consecutive patients (IVTA group, 20 
eyes; IVB group, 38 eyes) with DME. The major inclusion 
criteria for the study included 1) decreased best-corrected 
visual acuity (BCVA) caused by DME, 2) definite retinal 
thickening resulting from DME on clinical examination in-
volving the center of the macula and assessed to be the main JH Song, et al. Triamcinolone and Bevacizumab for Macular Edema
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Table 1. Baseline characteristics
IVTA group 
(20 eyes) 
IVB group 
(38 eyes)
p-value
Age (yr)   57.1 ± 10.8   59.3 ± 12.1 0.454
Gender
* (M:F) 8:12 24:14 0.163
Hypertension
* 5 9 0.241
HbA1c
† (mg/dL)   7.21 ± 1.09   7.58 ± 1.17 0.372
BCVA
† (logMAR)   0.67 ± 0.40   0.51 ± 0.31 0.115
CMT
† (μm) 400.4 ± 94.9 372.6 ± 99.5 0.148
IOP
† (mmHg)   14.9 ± 2.99  16.1 ± 3.34 0.274
IVTA = intravitreal triamcinolone acetonide; IVB = intravitreal 
bevacizumab; BCVA = best-corrected visual acuity; logMAR = 
logarithm of the minimum angle of resolution; CMT = central 
macular thickness; IOP = intraocular pressure.
*Tested using the chi-square test; 
†Tested using the Mann-Whitney 
test.
Table 2. BCVA (mean ± SD) at pre-injection and 2, 4, and 8 weeks post-injection
IVTA group IVB group
BCVA (logMAR) n p-value BCVA (logMAR) n p-value
Pre-injection 0.67 ± 0.40 20 0.51 ± 0.31 38
Post injection (2 wk) 0.56 ± 0.35 18 0.033
*† 0.42 ± 0.260 38 0.003
*‡
Post injection (4 wk) 0.55 ± 0.33 18 0.041
*†    43 ± 0.32 38 0.001
*‡
Post injection (8 wk) 0.43 ± 0.31 15 0.001
*† 0.43 ± 0.27 38 0.015
*‡
BCVA = best-corrected visual acuity; IVTA = intravitreal triamcinolone acetonide; IVB = intravitreal bevacizumab; logMAR = log of the 
minimum angle of resolution.
*Tested by comparison with pre-injection; 
†Tested using the Wilcoxon signed rank test; 
‡Tested using the paired t-test.
cause of visual loss, and 3) DME confirmed via slit-lamp bio-
microscopy or retinal thickness measured on 300 μm optical 
coherence tomography (OCT) or fluorescein angiography. 
Exclusion criteria included 1) macular edema with vitreous 
hemorrhage, 2) history of cataract surgery and/or vitrectomy 
within the previous six months or during the treatment period 
for diabetic macular edema, 3) prior treatment with IVTA or 
IVB (at any time): peribulbar steroid injection within the pre-
vious six months, photocoagulation for DME within the pre-
vious three months, 4) other ocular comorbidity that might 
exert influence on macular thickness or visual acuity such as 
central retinal vein occlusion, branch retinal vein occlusion, 
or uveitis, severe macular ischemia, and 5) history of pre-
vious glaucoma treatment such as medical and/or surgical 
treatment. Intravitreal injection of triamcinolone acetonide 4 
mg or bevacizumab 1.25 mg injection was performed with a 
30-gauge needle through the inferotemporal quadrant under 
sterile conditions using local anesthesia. The effects of intra-
vitreal injection for DME were evaluated according to BCVA 
and central macular thickness (CMT) using OCT (Stratus 
Zeiss Humphrey, San Leandro, CA, USA). OCT images were 
acquired using the fast macular thickness map scan con-
ducted by a single skilled examiner, and macular thickness 
was measured via retinal map analysis for the calculation of 
average macular thickness. BCVA measurements were based 
on the Snellen chart and were converted to the logarithm of 
the minimum angle of resolution (logMAR) scale for stat-
istical evaluation. Patients underwent eye examinations, in-
cluding intraocular pressure (IOP) with a tonopen applana-
tion tonometer, BCVA, stereoscopic biomicroscopy of the 
macula, and CMT measurement using OCT at pre-injection, 
as well as 2, 4, and 8 weeks after injection. After examination 
of OCT, repeated injections were performed for patients with 
decreased visual acuity. Glycosylated hemoglobin (HbA1c) 
and history of hypertension were measured at baseline. 
The data were analyzed using SPSS ver. 12.0 (SPSS Inc., 
Chicago, IL, USA). Comparisons within a group were ana-
lyzed using the Wilcoxon signed rank test, paired t-test, and 
the chi square test, and comparisons between the two groups 
were analyzed using the Mann-Whitney test. All p-values of 
less than 0.05 were considered statistically significant com-
pared to those pre-injection.
Results
 The groups treated with IVTA and IVB consisted of 20 
eyes (male eyes, 8; female eyes, 12) and 38 eyes (male eyes, 
24; female eyes, 14 eyes), respectively. The mean ages ± SD 
of the IVTA and IVB groups were 57.1 ± 10.8 years and 59.3 
± 12.1 years, respectively. The differences in mean age, gen-
der ratio, hypertension, HbA1c, baseline BCVA, CMT, and 
IOP between the two groups were not statistically significant 
(Table 1). 
In the IVTA group, BCVA (logMAR) ± SD at pre-in-
jection, 2, 4, and 8 weeks after injection was 0.67 ± 0.40, 0.56 
± 0.35 (p = 0.033), 0.55 ± 0.33 (p = 0.041), and 0.43 ± 0.31 (p 
= 0.001), respectively. The effects of IVTA on BCVA were 
consistent throughout the follow-up periods compared with 
the pre-injection status. In the IVB group, BCVA (logMAR) 
± SD at pre-injection, 2, 4, and 8 weeks after injection was 
0.51 ± 0.31, 0.42 ± 0.26 (p = 0.003), 0.43 ± 0.32 (p = 0.001), 
and 0.43 ± 0.27 (p = 0.015), respectively. BCVA at 2, 4, and 
8 weeks after injection in the IVB group showed significant 
improvement compared with the BVCA at pre-injection. The 
absolute value of BCVA improved more in the IVTA group 
than it did in the IVB group. BCVA was significantly better 
in the IVTA group during the follow-up period than it was in 
the IVB group (p < 0.05) (Table 2).
In the IVTA group, CMT (μm) ± SD values at pre-in-Korean J Ophthalmol Vol.25, No.3, 2011
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Fig. 1. Change in central macular thickness (CMT, μm) after intravitreal
triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB)
injections during the follow-up period. In the IVTA group, sig-
nificant reduction in CMT was observed throughout the follow-up 
period compared with the pre-injection level (p < 0.05). In the IVB 
group, reduction of CMT was not statistically significant (p < 0.05).
The IVTA group had a significant reduction of CMT during the fol-
low-up period compared with that in the IVB group (p < 0.05).
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Fig. 2. Change in intraocular pressure (IOP, mmHg) after intravitreal 
triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB)
injections during the follow-up period. In the IVTA group, sig-
nificant IOP elevation at 4 and 8 weeks after injection was observed 
compared with the pre-injection level (p < 0.05). In the IVB group, 
no significant IOP elevation was observed. The IVTA group had a 
significant increase in IOP during the follow-up period compared 
with that in the IVB group (p < 0.05).
jection, 2, 4, and 8 weeks after injection was 400.4 ± 94.9, 
332.8 ± 47.4 (p = 0.002), 287.5 ± 49.1 (p = 0.007), and 282.5 
± 49.6 (p = 0.043), respectively. In the IVB group, CMT (μm) 
± SD values at pre-injection, 2, 4, and 8 weeks after injection 
was 372.6 ± 99.5, 323.2 ± 72.4 (p = 0.077), 360.9 ± 50.3 (p = 
0.668), and 368.2 ± 88.6 (p = 0.830), respectively. The per-
centages of reduced CMT compared with that at pre-in-
jection in the IVTA group at 2, 4, and 8 weeks after injection 
were 17.9%, 28.2%, and 29.5%, and those in the IVB group 
were 13.3%, 3.2%, and 1.2%, respectively. The absolute val-
ue of CMT improved more in the IVTA group than it did in 
the IVB group. The reduction of CMT was statistically sig-
nificant in the IVTA group throughout the follow-up period, 
but this was not true in the IVB group. The IVTA group 
showed a significant reduction in CMT during the follow-up 
period compared with that in the IVB group (p < 0.05) (Fig. 1). 
Increased IOP (mmHg) values due to IVTA at pre-in-
jection, 2, 4, and 8 weeks after injection was 14.9 ± 2.99, 16.4 
± 3.05 (p = 0.086), 16.4 ± 2.03 (p = 0.026), and 18.3 ± 3.95 (p 
= 0.002), respectively. The IOP (mmHg) of IVB at pre-in-
jection and 2, 4, and 8 weeks after injection was 16.1 ± 3.34, 
15.4 ± 2.75 (p = 0.244), 16.0 ± 2.86 (p = 0.896), and 16.4 ± 
2.20 (p = 0.596), respectively. In the IVTA group, a sig-
nificant IOP increase was observed at 4 and 8 weeks after in-
jection compared with the pre-injection level. Additionally, 
two patients showed an IOP increase requiring reduction 
treatment at eight weeks after injection which normalized af-
ter temporary topical eye drop treatment. However, in the 
IVB group, there was no significant IOP increase or patient 
requiring IOP reduction treatment. The IVTA group had a 
significant IOP increase during the follow-up period com-
pared with that in the IVB group (p < 0.05) (Fig. 2). 
Discussion
 Macular edema is the main cause of decreased visual acui-
ty for several diseases. Approximately 10% of all diabetic 
patients manifest macular edema, with 40% of the patients 
showing involvement of the center of the macula [16].
Paccola et al. [17] reported that a more favorable BCVA 
improvement was observed with IVTA compared with that 
of IVB as early as four weeks after treatment and persisting 
up to 12 weeks. Similarly, other reports have shown sig-
nificant visual acuity improvements at the same study points 
after IVTA [4,7,8]. In the present study, BCVA of the IVTA 
group improved significantly at 2, 4, and 8 weeks after in-
jection, as in previous reports [4,7,8,17]. The BCVA in the 
IVB group showed improvement during the eight weeks after 
injection compared to the pre-injection status. However, 
BCVA was slightly decreased at four and eight weeks after 
injection compared with that at two weeks after injection. 
This BCVA result in the IVB group is more shorter than pre-
vious reports [7,18,19]. 
There are several possible reasons for the reduced effec-
tiveness compared to those of other reports [7,18,19]. In our 
clinic, IVB injection was performed with the previously 
multiple-fractionated bevacizumab syringe. The preloaded 
syringe was stored at 4℃ in the dark. This method was 
based on a recent study showing that refrigerated bev-
acizumab can be stored for up to three weeks at 4℃ without 
loss of efficacy and can remain sterile for up to six months 
at 4℃ [20-22]. However, in our clinic, after withdrawal of 
multiple doses from the single-use vial, inadvertent change 
in the anti-vascular endothelial growth factor (VEGF) anti-
body concentration or activity may have resulted. This re-
duction in effective anti-VEGF antibody concentration may 
have lead to a decreased effect of IVB. Therefore, the 
BCVA was significantly better in the IVTA group than it 
was in the IVB group during the follow-up period (p < 
0.05). The result from the present study is similar to those of 
previous reports; the effects of IVTA were more prominent JH Song, et al. Triamcinolone and Bevacizumab for Macular Edema
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with longer duration compared to those of IVB [17,19].
Paccola et al. [17] reported that a single IVTA had more ef-
fect on reduction of CMT in patients with DME compared 
with one IVB during an eight-week period. Oh et al. [18] also 
reported that CMT reduction was maintained until three 
months after IVTA injection, while in the IVB group, CMT 
reduction was maintained until two months after injection. 
Massin et al. [6] also demonstrated a significant reduction of 
CMT for at least three months. In the current study, CMT re-
duction was significantly maintained until eight weeks after 
the IVTA injection, while the CMT in the IVB group began 
to decrease four weeks after IVB injection. This CMT reduc-
tion effect in the IVTA group is similar to those in previous 
reports; however the CMT reduction effect in the IVB group 
is less prominent with a shorter duration compared to those 
of previous reports. The reason for the CMT result in the IVB 
group may be the same reason as that provided for the BCVA 
result. Furthermore, the CMT reduction effect in the IVB 
group was statistically insignificant throughout eight weeks 
after IVB injection, unlike other reports showing statistical 
significance [17-19]. 
Previous reports regarding the effects of IVB in DME 
showed a correlation between BCVA and CMT and statistical 
significance of recovery of BCVA and CMT [10,11,17-19]. 
However, in the present study, a correlation between BCVA 
and CMT was not observed because improvement of BCVA 
in the IVB group was statistically significant, while CMT re-
duction was statistically insignificant. Therefore, a further 
study regarding the reasons for the discordance between 
BCVA and CMT should be performed.
Possible causes of differences between the IVTA and IVB 
groups in the duration and effectiveness may include the fol-
lowing: 1) bevacizumab only has an effect on inhibition of 
VEGF, while 2) triamcinolone acetonide has multiple effects 
such as inhibiting the expression of both VEGF and the 
VEGF gene and inhibition of inflammatory cytokines asso-
ciated with vascular permeability [23]. All of the above-men-
tioned reasons also may have had an effect on the results of 
the current study.
The complications of IVTA included IOP elevation, cata-
ract formation or progression, retinal detachment, and 
endophthalmitis. Among the complications, IOP elevation is 
the most common [24-27]. Oh et al. [18] reported that five of 
40 eyes developed temporary IOP elevation and required 
temporary treatment. Martidis et al. [4] also reported cataract 
progression and increased incidence of glaucoma after 
IVTA. In the current study, two patients in the IVTA group 
showed IOP increase requiring treatment at eight weeks 
which normalized after temporary treatment. However, no 
cataract formation or progression which affected visual acui-
ty was observed in either group during the follow-up period. 
In the IVB group, there was no significant IOP increase or 
patient requiring IOP reduction treatment. The difference in 
IOP increase effect among the two groups was statistically 
significant during the follow-up period (p < 0.05). Audren et 
al. [28] reported that, although no remarkable complication 
due to intravitreal injection was observed during the fol-
low-up period, IVTA has potential side effects including an 
increase in IOP and cataract development. 
Chan et al. [29] reported that, even if the ocular hyper-
tensive effects were similar between the injection types, the 
cumulative effects of the intraocular steroids would lead to 
increased cataractogenesis, and each injection exposes the 
eye to the small but serious risk of infective endophthalmitis. 
Retrospective reports of IVTA injection indicate a per-in-
jection endophthalmitis risk between 0% and 0.87% [30-33]. 
Studies regarding the endophthalmitis incidence of IVB re-
ported a 0.019% to 0.16% incidence after injections [34-37]. 
Severe complications such as infectious endophthalmitis or 
retinal detachment were not observed within the follow-up 
period in either group in the present study.
Consequently, both the IVTA and IVB treatments were effec-
tive for recovery of visual loss caused by diabetic retinopathy. 
However, the effects of IVTA for BCVA were more favorable 
than those of the IVB and were consistent throughout eight 
weeks after injection. IVTA significantly reduced the CMT 
during eight weeks after injection, while IVB did not have a 
significant impact on CMT during the follow-up period. 
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